DE60232739D1 - Aktivator des peroxisomproliferator-aktivierten rezeptors delta - Google Patents

Aktivator des peroxisomproliferator-aktivierten rezeptors delta

Info

Publication number
DE60232739D1
DE60232739D1 DE60232739T DE60232739T DE60232739D1 DE 60232739 D1 DE60232739 D1 DE 60232739D1 DE 60232739 T DE60232739 T DE 60232739T DE 60232739 T DE60232739 T DE 60232739T DE 60232739 D1 DE60232739 D1 DE 60232739D1
Authority
DE
Germany
Prior art keywords
activator
peroxisomproliferator
activated receptor
receptor delta
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60232739T
Other languages
English (en)
Inventor
Shogo Sakuma
Tomio Yamakawa
Takashi Kanda
Seiichiro Masui
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nippon Chemiphar Co Ltd
Original Assignee
Nippon Chemiphar Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Chemiphar Co Ltd filed Critical Nippon Chemiphar Co Ltd
Application granted granted Critical
Publication of DE60232739D1 publication Critical patent/DE60232739D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
DE60232739T 2001-10-12 2002-10-09 Aktivator des peroxisomproliferator-aktivierten rezeptors delta Expired - Lifetime DE60232739D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001315694 2001-10-12
PCT/JP2002/010472 WO2003033493A1 (fr) 2001-10-12 2002-10-09 Activateur du recepteur $g(d) active par le proliferateur de peroxisome

Publications (1)

Publication Number Publication Date
DE60232739D1 true DE60232739D1 (de) 2009-08-06

Family

ID=19133818

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60232739T Expired - Lifetime DE60232739D1 (de) 2001-10-12 2002-10-09 Aktivator des peroxisomproliferator-aktivierten rezeptors delta

Country Status (17)

Country Link
US (2) US7119104B2 (de)
EP (1) EP1445258B1 (de)
JP (1) JP4276074B2 (de)
KR (1) KR100933652B1 (de)
CN (1) CN1293076C (de)
AT (1) ATE434616T1 (de)
AU (1) AU2002335231B2 (de)
BR (1) BRPI0213243B8 (de)
CA (1) CA2463569C (de)
CY (1) CY1110355T1 (de)
DE (1) DE60232739D1 (de)
DK (1) DK1445258T3 (de)
ES (1) ES2326411T3 (de)
IL (2) IL161351A0 (de)
MX (1) MXPA04003398A (de)
PT (1) PT1445258E (de)
WO (1) WO2003033493A1 (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1445258B1 (de) * 2001-10-12 2009-06-24 Nippon Chemiphar Co., Ltd. Aktivator des peroxisomproliferator-aktivierten rezeptors delta
EP1637161A4 (de) * 2003-04-22 2007-06-27 Astellas Pharma Inc MITTEL ZUR BEHANDLUNG VON NEURODEGENERATIVEN ERKRANKUNGEN DES GEHIRNS MIT PPAR [delta] AGONIST
ES2378435T3 (es) 2003-09-19 2012-04-12 Janssen Pharmaceutica N.V. �?cidos 4-((fenoxialquil)tio)-fenoxiacéticos y análogos
WO2005060958A1 (en) * 2003-12-19 2005-07-07 Kalypsys, Inc. (5- (2-phenyl)-thiazol-5-ylmethoxy)-indol-1-yl) -acetic acid derivatives and related compounds as modulators of the human ppar-delta receptor for the treatment of metabolic disorders such as type 2 diabetes
US20080125403A1 (en) 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders
JP2007536343A (ja) 2004-05-05 2007-12-13 ノボ　ノルディスク　アクティーゼルスカブ Ｐｐａｒアゴニストとしてのフェノキシ酢酸誘導体
WO2005105736A1 (en) 2004-05-05 2005-11-10 Novo Nordisk A/S Novel compounds, their preparation and use
EP1794159B1 (de) * 2004-09-11 2012-08-01 Sanofi-Aventis Deutschland GmbH 7-azaindole und ihre verwendung als ppar-agonisten
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
EP1899302B1 (de) 2005-06-30 2011-10-19 High Point Pharmaceuticals, LLC Phenoxyessigsäuren als ppar-delta-aktivatoren
CA2614315A1 (en) * 2005-07-06 2007-01-11 Nippon Chemiphar Co., Ltd. Activator of peroxisome proliferator activated receptor d
JP2009509932A (ja) * 2005-09-07 2009-03-12 プレキシコン，インコーポレーテッド Ｐｐａｒ活性化合物
JO3006B1 (ar) 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
NZ568488A (en) 2005-12-22 2011-07-29 High Point Pharmaceuticals Llc Phenoxy acetic acids as PPAR delta activators
EP1999098A2 (de) 2006-03-09 2008-12-10 High Point Pharmaceuticals, LLC Verbindungen, die die ppar-aktivität modulieren, ihre herstellung und ihre verwendung
PE20080188A1 (es) * 2006-04-18 2008-03-10 Janssen Pharmaceutica Nv Derivados del acido benzoazepin-oxi-acetico como agonistas de ppar-delta usados para aumentar hdl-c, reducir ldl-c y reducir colesterol
NZ572268A (en) * 2006-04-18 2011-09-30 Nippon Chemiphar Co Activating agent for peroxisome proliferator activated receptor delta (ppar)
JPWO2008016175A1 (ja) * 2006-08-03 2009-12-24 日本ケミファ株式会社 ペルオキシソーム増殖剤活性化受容体の活性化剤
ES2393424T3 (es) * 2007-05-21 2012-12-21 Senju Pharmaceutical Co., Ltd. Agente farmacéutico que contiene un agonista de PPAR-delta
WO2008154023A1 (en) * 2007-06-11 2008-12-18 Cerenis Therapeutics S.A. Novel uses of ppar delta agonists
HUE039145T2 (hu) * 2008-04-15 2018-12-28 Nippon Chemiphar Co Aktivátor peroxim proliferátor-aktivált receptorhoz
WO2010047982A1 (en) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2010051206A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
EP2464349A2 (de) * 2009-08-14 2012-06-20 Cerenis Therapeutics S.A. Verwendung von ppar-delta-liganden für die behandlung oder prävention von entzündungen oder energiestoffwechsel-/produktionsbedingten erkrankungen
EP2483407A2 (de) 2009-09-30 2012-08-08 President and Fellows of Harvard College Verfahren zur autophagie-modulation durch modulation autophagie-verstärkender genprodukte
JP2013006769A (ja) * 2009-10-08 2013-01-10 Nippon Chemiphar Co Ltd ペルオキシソーム増殖剤活性化受容体の活性化剤
AU2011218830B2 (en) 2010-02-25 2014-07-24 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2012027331A1 (en) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
CN103476258B (zh) 2011-02-25 2017-04-26 默沙东公司 用作抗糖尿病药剂的新的环状氮杂苯并咪唑衍生物
EP2880028B1 (de) 2012-08-02 2020-09-30 Merck Sharp & Dohme Corp. Antidiabetische tricyclische verbindungen
CA2899237A1 (en) 2013-01-31 2014-08-07 Senju Pharmaceutical Co., Ltd. Clear aqueous solution
CN105007918B (zh) 2013-01-31 2018-06-15 千寿制药株式会社 稳定的水性液体制剂
CA2898482A1 (en) 2013-02-22 2014-08-28 Linda L. Brockunier Antidiabetic bicyclic compounds
EP2970119B1 (de) 2013-03-14 2021-11-03 Merck Sharp & Dohme Corp. Neuartige indolderivate als antidiabetika
EP3756661A1 (de) 2013-09-09 2020-12-30 vTv Therapeutics LLC Verwendung eines ppar-delta-agonisten zur behandlung von muskelatrophie
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
JPWO2017195875A1 (ja) * 2016-05-12 2019-03-22 日本ケミファ株式会社 創傷治療剤
EP3551176A4 (de) 2016-12-06 2020-06-24 Merck Sharp & Dohme Corp. Antidiabetische heterocyclische verbindungen
EP3558298A4 (de) 2016-12-20 2020-08-05 Merck Sharp & Dohme Corp. Antidiabetische spirochromanverbindungen
US10847272B2 (en) * 2016-12-30 2020-11-24 Nuscale Power, Llc Control rod drive mechanism (CRDM) with remote disconnect mechanism
US11634387B2 (en) 2019-09-26 2023-04-25 Abionyx Pharma Sa Compounds useful for treating liver diseases
CN113912547B (zh) 2020-07-10 2024-04-30 成都凡诺西生物医药科技有限公司 取代苯丙咪唑类衍生物及其应用
WO2022189856A1 (en) * 2021-03-08 2022-09-15 Abionyx Pharma Sa Compounds useful for treating liver diseases
WO2023147309A1 (en) 2022-01-25 2023-08-03 Reneo Pharmaceuticals, Inc. Use of ppar-delta agonists in the treatment of disease
CN115215856A (zh) * 2022-08-19 2022-10-21 沈阳药科大学 一种PPARδ激动剂福那德帕及其中间体的制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089514A (en) * 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
US5089541A (en) * 1990-11-23 1992-02-18 Shell Oil Company Removal of hydrogenation catalyst from polymer solutions by contact with activated carbon
GB9027023D0 (en) 1990-12-12 1991-01-30 Wellcome Found Anti-atherosclerotic aryl compounds
HUT64023A (en) 1991-03-22 1993-11-29 Sandoz Ag Process for producing aminoguanidine derivatives and pharmaceutical compositions comprising such compounds
GB9426448D0 (en) 1994-12-30 1995-03-01 Wellcome Found Process
WO1996020925A1 (fr) * 1995-01-06 1996-07-11 Toray Industries, Inc. Derive heterocyclique benzocondense et son utilisation
CA2171702A1 (en) * 1995-03-14 1996-09-15 Takashi Sohda Benzofuran compounds and their use
AU5121796A (en) 1995-05-08 1996-11-29 Nippon Chemiphar Co. Ltd. 2,4-thiazolidinedione or oxazolidinedione derivatives and hy poglycemic agent
JP2000503984A (ja) 1996-01-22 2000-04-04 藤沢薬品工業株式会社 チアゾリルベンゾフラン誘導体およびその医薬組成物
EP0888278B1 (de) 1996-02-02 2003-07-23 Merck & Co., Inc. Antidiabetische mittel
US20020032330A1 (en) * 1996-12-24 2002-03-14 Yutaka Nomura Propionic acid derivatives
DE69840510D1 (de) * 1997-07-24 2009-03-12 Astellas Pharma Inc Medizinische zusammensetzungen mit cholesterin erniedrigender wirkung
US6589969B1 (en) * 1998-10-16 2003-07-08 Ono Pharmaceutical Co., Ltd. Carboxylic acid derivatives and drugs containing the same as the active ingredient
JP2001354671A (ja) * 2000-04-14 2001-12-25 Nippon Chemiphar Co Ltd ペルオキシソーム増殖剤応答性受容体δの活性化剤
US7176224B2 (en) * 2000-08-23 2007-02-13 Eli Lilly And Company Oxazolyl-aryloxyacetic acid derivatives and their use as PPAR agonists
US7105551B2 (en) * 2000-12-20 2006-09-12 Smithkline Beecham Corporation Thiazole derivatives for treating PPAR related disorders
GB0031109D0 (en) * 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
US7091225B2 (en) * 2000-12-20 2006-08-15 Smithkline Beecham Corporation Substituted oxazoles and thiazoles as hPPAR alpha agonists
GB0113231D0 (en) * 2001-05-31 2001-07-25 Glaxo Group Ltd Chemical compounds
JP4421895B2 (ja) * 2001-08-10 2010-02-24 日本ケミファ株式会社 ペルオキシソーム増殖剤応答性受容体δの活性化剤
EP1445258B1 (de) * 2001-10-12 2009-06-24 Nippon Chemiphar Co., Ltd. Aktivator des peroxisomproliferator-aktivierten rezeptors delta
US6867224B2 (en) * 2002-03-07 2005-03-15 Warner-Lambert Company Compounds that modulate PPAR activity and methods of preparation

Also Published As

Publication number Publication date
BRPI0213243B8 (pt) 2021-05-25
BR0213243A (pt) 2005-01-04
IL161351A0 (en) 2004-09-27
CA2463569A1 (en) 2003-04-24
EP1445258A1 (de) 2004-08-11
CY1110355T1 (el) 2015-04-29
DK1445258T3 (da) 2009-10-12
KR20040053164A (ko) 2004-06-23
US20070027196A1 (en) 2007-02-01
CN1293076C (zh) 2007-01-03
MXPA04003398A (es) 2004-11-22
US7119104B2 (en) 2006-10-10
CN1568323A (zh) 2005-01-19
JP4276074B2 (ja) 2009-06-10
IL161351A (en) 2012-12-31
PT1445258E (pt) 2009-07-02
US20050096363A1 (en) 2005-05-05
WO2003033493A1 (fr) 2003-04-24
ATE434616T1 (de) 2009-07-15
CA2463569C (en) 2012-05-15
AU2002335231B2 (en) 2008-05-08
JPWO2003033493A1 (ja) 2005-02-03
KR100933652B1 (ko) 2009-12-23
EP1445258B1 (de) 2009-06-24
EP1445258A4 (de) 2006-01-04
ES2326411T3 (es) 2009-10-09
US7402597B2 (en) 2008-07-22
BRPI0213243B1 (pt) 2021-03-16

Similar Documents

Publication Publication Date Title
DE60232739D1 (de) Aktivator des peroxisomproliferator-aktivierten rezeptors delta
WO2003016291A1 (fr) Activateur du recepteur $g(d) sensible au proliferateur de peroxysome
ATE542805T1 (de) Ppar-delta aktivatoren
MX9709951A (es) Derivados de benzamida y su uso como antagonistas de vasopresina.
IL147651A0 (en) Isoxazoline derivative and herbicide containing the same as the active ingredient
DK0378518T3 (da) Adenosinderivater med farmaceutisk aktivitet som antihypertensiva
HRP20070286T3 (en) Substituted diketopiperazines and their use as oxytocyn antagonists
FI923033A (fi) N-fenyltioureaderivat och farmaceutisk anvaendning
ATE285410T1 (de) Naphthyridinderivate oder salze davon
NO20042010L (no) 4-imidazolin-2-on forbindelser
DK0807627T3 (da) Anilidforbindelser som ACAT-inhibitorer
DE60016384D1 (de) Chondrogonese promotoren und indolin-2-on derivate
TWI265161B (en) Oxime compounds, their use, and intermediates for their production
ATE504583T1 (de) 4-imidazolin-2-onverbindungen
IL136510A (en) Acylated hetero-alicyclic derivatives and pharmaceutical compositions containing the same
MY130817A (en) Herbicides
DE69828087D1 (de) Aminderivate
DE60211686D1 (de) Pkb-3564-substanz mit die gefässneubildung hemmender wirkung
DE60230924D1 (de) 2-substituierte vitamin-d-derivate

Legal Events

Date Code Title Description
8364 No opposition during term of opposition